Search Result

Results for "

FLT3-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (27) Akt (2) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (11) Bcr-Abl (1) Btk (1) c-Kit (3) c-Met/HGFR (1) CDK (1) Checkpoint Kinase (Chk) (1) ERK (1) FAK (1) HDAC (1) IKZF Family (1) Insulin Receptor (1) IRAK (2) JAK (7) Ligands for Target Protein for PROTAC (1) MEK (1) MNK (1) Molecular Glues (1) mTOR (2) PDGFR (3) PI3K (2) PROTACs (3) RET (1) STAT (4) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (1) TGF-beta/Smad (2) TGF-β Receptor (2) Trk Receptor (2) VEGFR (2)
By Research Areas:	Cancer (30)

By Targets:

FLT3 (27)

Akt (2)

Anaplastic lymphoma kinase (ALK) (2)

Apoptosis (11)

Bcr-Abl (1)

Btk (1)

c-Kit (3)

c-Met/HGFR (1)

CDK (1)

Checkpoint Kinase (Chk) (1)

ERK (1)

FAK (1)

HDAC (1)

IKZF Family (1)

Insulin Receptor (1)

IRAK (2)

JAK (7)

Ligands for Target Protein for PROTAC (1)

MEK (1)

MNK (1)

Molecular Glues (1)

mTOR (2)

PDGFR (3)

PI3K (2)

PROTACs (3)

RET (1)

STAT (4)

TAM Receptor (1)

Target Protein Ligand-Linker Conjugates (1)

TGF-beta/Smad (2)

TGF-β Receptor (2)

Trk Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (30)

Inhibitors & Agonists

Peptides

Targets Recommended: FLT3 Dan family AIM2 NEKs CD44

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12960

SKLB4771 FLT3-IN-1	FLT3 c-Kit Apoptosis	Cancer
SKLB4771 is a potent and selective Flt3 inhibitor with an IC₅₀ value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .

HY-130247

Flonoltinib 1 Publications Verification JAK2/FLT3-IN-1	JAK FLT3 Apoptosis	Cancer
Flonoltinib is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity .

HY-130247A

Flonoltinib TFA 1 Publications Verification JAK2/FLT3-IN-1 TFA	JAK FLT3 Apoptosis	Cancer
Flonoltinib TFA is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity .

HY-155195

FLT3/CHK1-IN-1	FLT3	Cancer
FLT3/CHK-IN-1 (Compound 18) is a dual inhibitor of FLT3/CHK1. FLT3/CHK-IN-1 is more than 1700 times more selective to c-KI T and greatly reduces hERG affinity with an IC₅₀ value of 58.4 μM. FLT3/CHK-IN-1 inhibits tumor growth in mouse xenotransplantation models inoculated with MV-4-11 cells .

HY-130247B

Flonoltinib monomaleate JAK2/FLT3-IN-1 monomaleate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-130247C

Flonoltinib sulfate JAK2/FLT3-IN-1 sulfate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib maleate has anti-cancer activity .

HY-145865

c-Met/MEK1/Flt-3-IN-1	Apoptosis	Cancer
Antiproliferative against-3 (comp 33) shows a prominent activity against Hela (IC₅₀ = 0.21 µM), A549 (IC₅₀ = 0.39 µM), and MCF-7 (IC₅₀ = 0.33 µM), respectively. Antiproliferative against-3 (comp 33) also dose dependently induces apoptosis by arresting A549 cells at G1 phase .

HY-162367

FLT3/CHK1-IN-2	FLT3 Checkpoint Kinase (Chk)	Cancer
FLT3/CHK1-IN-2 (Compound 30) is a dual inhibitor of *FLT3* and CHK1, with IC₅₀s of 25.63, 16.39, 22.80 nM for CHK1, FLT3-WT, and FLT-D835Y respectively. FLT3/CHK1-IN-2 has favorable oral PK properties and kinase selectivity. FLT3/CHK1-IN-2 can be used for research of acute myeloid leukemia (AML) .

HY-175040

*PROTAC FLT3/GSPT1/IKZF1/3 degrader-1*	PROTACs Molecular Glues FLT3 IKZF Family	Cancer
PROTAC FLT3/GSPT1/IKZF1/3 degrader-1 is a FLT3 PROTAC degrader (DC50 = 1.2 nM). PROTAC FLT3/GSPT1/IKZF1/3 degrader-1 functions as a molecular glue to degrade cereblon substrates GSPT1 and IKZF1/3. PROTAC FLT3/GSPT1/IKZF1/3 degrader-1 exhibits antiproliferative activity against drug-resistant acute myeloid leukemia (AML) cells and is potentially useful in AML research. (Pink: FLT3/GSPT1/IKZF1/3 ligand: (HY-169374); Blue: Thalidomide ligand: (HY-14658); Black: Kinker; Thalidomide ligand + linker: (HY-W1123823)) .

HY-169076

FLT3/HDAC-IN-1	FLT3 HDAC Apoptosis	Cancer
FLT3/HDAC-IN-1 is a dual inhibitor of *FLT3/HDAC, with IC₅₀* values of 30.4, 52.4, and 14.7 nM for FLT3, HDAC1, and HDAC3, respectively. FLT3/HDAC-IN-1 can induce apoptosis in MV-4-11 cells and has anti-proliferative effects on FLT3 mutant-transformed BaF3 cells. FLT3/HDAC-IN-1 is being researched for its potential in treating hard-to-treat solid tumors and hematological malignancies .

HY-19897

4SC-203	FLT3 VEGFR	Cancer
4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs .

HY-15166B

(E/Z)-Zotiraciclib citrate Maximum Cited Publications 6 Publications Verification (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and *FLT3* inhibitor .

HY-114323

PROTAC FLT-3 degrader 1	PROTACs FLT3 Apoptosis STAT MEK ERK	Cancer
PROTAC FLT-3 degrader 1 is an effective and selective FLT-3 PROTAC degrader with an IC₅₀ of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor. (Pink: FLT3 ligand (HY-168702); Black: Linker (HY-124380); Blue: VHL ligand (HY-125845)) .

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent *FLT3/TrKA* dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML) .

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-131230

Desmorpholinyl Quizartinib-PEG2-COOH	Target Protein Ligand-Linker Conjugates	Cancer
Desmorpholinyl Quizartinib-PEG2-COOH incorporates a ligand for FLT-3, and a PEG-based PROTAC linker. Desmorpholinyl Quizartinib-PEG2-COOH can be used in the synthesis of PROTAC FLT-3 degrader 1 (HY-114323). PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC₅₀ 0.6 nM .

HY-124502

UNC4203	TAM Receptor FLT3	Cancer
UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC₅₀s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively .

HY-13493

AC710	PDGFR c-Kit FLT3	Cancer
AC710 is a potent PDGFR inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-13493A

AC710 Mesylate	PDGFR	Cancer
AC710 Mesylate is a potent PDGFR inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-168702

FLT3 ligand-2	Ligands for Target Protein for PROTAC	Cancer
FLT3 ligand-2 is a Ligand for Target Protein for PROTAC. FLT3 ligand-2 can be used to synthesize PROTAC FLT-3 degrader 1 (HY-114323) .

HY-159953

IRAK1/4/pan-FLT3 Kinase-IN-1	IRAK FLT3	Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 (Compound 31) is a potent inhibitor of IRAK1, IRAK4, and *FLT3* kinases, with an IC₅₀ of 5 nM for IRAK1, 0.6 nM for IRAK4, and less than 0.5 nM for *FLT3. IRAK1/4/pan-FLT3 Kinase*-IN-1 has good pharmacokinetic properties and shows promising potential for research in acute myeloid leukemia, with a survival prolongation effect comparable to that of Gilteritinib (HY-12432) .

HY-109179A

Itacnosertib hydrochloride TP-0184 hydrochloride	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for *FLT3, ACVR1* (ALK2, IC₅₀=8 nM) and JAK2 (IC₅₀=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity .

HY-101549A

MRX-2843 hydrochloride UNC2371 hydrochloride	FLT3	Cancer
MRX-2843 hydrochloride is an orally active, ATP-competitive dual MERTK and *FLT3* tyrosine kinases inhibitor (TKI) with enzymatic IC₅₀s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively .

HY-109179

Itacnosertib TP-0184	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib (TP-0184) is the inhibitor for *FLT3, ACVR1* (ALK2, IC₅₀=8 nM) and JAK2 (IC₅₀=8540 nM). Itacnosertib exhibits anti-leukemic activity .

HY-101549

MRX-2843 5 Publications Verification UNC2371	FLT3	Cancer
MRX-2843 (UNC2371) is an orally active, ATP-competitive dual MERTK and *FLT3* tyrosine kinases inhibitor (TKI) with enzymatic IC₅₀s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively .

HY-160787

NCGC1481	FLT3 IRAK	Cancer
NCGC1481 is an inhibitor of *FLT3, IRAK1*, and IRAK4, with IC₅₀ values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. NCGC1481 can effectively overcome the adaptive resistance of leukemia cells to *FLT3* inhibitors and has antileukemic activity .

HY-B0791

Altiratinib 1 Publications Verification DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, *FLT3, Trk1*, Trk2, and Trk3 respectively.

HY-171146

HSN748	FLT3 Bcr-Abl RET PDGFR MNK	Cancer
HSN748 is a Ponatinib (HY-12047) analogue and a multikinase inhibitor. HSN748 has inhibitory activity on *FLT3, ABL1*, RET, PDGFRα/β, MNK1, MNK2 and other kinases. HSN748 can inhibit the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines and can be used in the study of leukemia .

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-158325

*PROTAC FLT-3* degrader 4**	PROTACs FLT3 Apoptosis	Cancer
PROTAC FLT-3 degrader 4 is an orally active CRBN-based *FLT3-PROTAC* degrader that potently induces FLT3-ITD degradation through the ubiquitin-proteasome system. PROTAC FLT-3 degrader 4 shows highly selective to FLT3-ITD mutant acute myeloid leukemia (AML) cells. (Blue: CRBN ligand, Black: linker; Pink: FLT3 inhibitor) .

HY-170576

FLT3-IN-28	FLT3 STAT Apoptosis	Cancer
FLT3-IN-28 (Compound 12y) is an orally active *FLT3* inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the *FLT3* internal tandem duplication (ITD) mutation, with IC₅₀ values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of *FLT3* and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

FLT3-​IN-​1

Inhibitors & Agonists

Peptides

FLT3-IN-1